HSP27 inhibitor J2
Based on 6 publication(s) in Google Scholar
HSP27 inhibitor J2 (J2) is a HSP27 inhibitor, which significantly induces abnormal HSP27 dimer formation and inhibits a production of HSP27 giant polymers, thereby having an effect of inhibiting a chaperone function of the HSP27 and reducing a cell protection function thereof. HSP27 inhibitor J2 (J2) remarkably enhances the antiproliferative activity of 17-AAG and sensitizes cisplatin-induced lung cancer cell growth inhibition.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.70%
- CAS No.: 2133499-85-9
- Formule: C13H12O4S
- Masse moléculaire:264.30
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) HSP27 inhibitor J2
More
Activité biologique
HSP27[2]
HSP27 inhibitor J2 (10 μM; 12 h) induces significant abnormal HSP27 dimer formation in NCI-H460[1].
HSP27 inhibitor J2 (10 μM; 24 h) increases 17-AAG-induced apoptosis in shCTRL cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2133499-85-9
-
Appearance Solid
-
Masse moléculaire 264.30
-
Formule C13H12O4S
-
Color Off-white to light yellow
-
SMILES
O=C1C=C(C)OC2=C1C(O)=CC(OCC3SC3)=C2
-
Synonyms
J2
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
J Exp Clin Cancer Res
2023 Apr 4;42(1):80. PMID: 37016377 -
Int Immunopharmacol
Targeting the S100A9/P38 MAPK/HSPB1 axis as a novel approach for aortic dissection therapy. [Abstract]2025 Mar 6:149:114225. PMID: 39904041 -
Int J Mol Sci
NFE2L2 and STAT3 Converge on Common Targets to Promote Survival of Primary Lymphoma Cells. [Abstract]2023 Jul 18;24(14):11598. PMID: 37511362 -
Sci Rep
Relationship between intrathrombotic appearance of HSP27 and HSP70 and thrombus ages in a murine model of deep vein thrombosis. [Abstract]2023 Dec 16;13(1):22416. PMID: 38104135 -
Biomedicines
c-Myc Sustains Pancreatic Cancer Cell Survival and mutp53 Stability through the Mevalonate Pathway. [Abstract]2022 Oct 5;10(10):2489. PMID: 36289751 -
Solvant et solubilité
DMSO : 20 mg/mL (75.67 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 5 mg/mL (18.92 mM); Suspended solution; Need ultrasonic and warming and heat to 48°C
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (273 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.7836 mL | 18.9179 mL | 37.8358 mL | 94.5895 mL |
| 5 mM | 0.7567 mL | 3.7836 mL | 7.5672 mL | 18.9179 mL | |
| 10 mM | 0.3784 mL | 1.8918 mL | 3.7836 mL | 9.4589 mL | |
| 15 mM | 0.2522 mL | 1.2612 mL | 2.5224 mL | 6.3060 mL | |
| 20 mM | 0.1892 mL | 0.9459 mL | 1.8918 mL | 4.7295 mL | |
| 25 mM | 0.1513 mL | 0.7567 mL | 1.5134 mL | 3.7836 mL | |
| 30 mM | 0.1261 mL | 0.6306 mL | 1.2612 mL | 3.1530 mL | |
| 40 mM | 0.0946 mL | 0.4729 mL | 0.9459 mL | 2.3647 mL | |
| 50 mM | 0.0757 mL | 0.3784 mL | 0.7567 mL | 1.8918 mL | |
| 60 mM | 0.0631 mL | 0.3153 mL | 0.6306 mL | 1.5765 mL |